These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 23958313)

  • 21. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.
    Xu L; Anchordoquy T
    J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivery of therapeutic oligonucleotides with cell penetrating peptides.
    Boisguérin P; Deshayes S; Gait MJ; O'Donovan L; Godfrey C; Betts CA; Wood MJ; Lebleu B
    Adv Drug Deliv Rev; 2015 Jun; 87():52-67. PubMed ID: 25747758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide nanoparticles for oligonucleotide delivery.
    Lehto T; Ezzat K; Langel U
    Prog Mol Biol Transl Sci; 2011; 104():397-426. PubMed ID: 22093225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides.
    Hassane FS; Abes R; El Andaloussi S; Lehto T; Sillard R; Langel U; Lebleu B
    J Control Release; 2011 Jul; 153(2):163-72. PubMed ID: 21536086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
    Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
    J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing.
    Baoum A; Ovcharenko D; Berkland C
    Int J Pharm; 2012 May; 427(1):134-42. PubMed ID: 21856394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitosan enhances gene delivery of oligonucleotide complexes with magnetic nanoparticles-cell-penetrating peptide.
    Dowaidar M; Nasser Abdelhamid H; Hällbrink M; Langel Ü; Zou X
    J Biomater Appl; 2018 Sep; 33(3):392-401. PubMed ID: 30223733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.
    Johannes L; Lucchino M
    Nucleic Acid Ther; 2018 Jun; 28(3):178-193. PubMed ID: 29883296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide delivery with cell surface binding and cell penetrating Peptide amphiphile nanospheres.
    Mumcuoglu D; Sardan M; Tekinay T; Guler MO; Tekinay AB
    Mol Pharm; 2015 May; 12(5):1584-91. PubMed ID: 25828697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
    Chan DP; Deleavey GF; Owen SC; Damha MJ; Shoichet MS
    Biomaterials; 2013 Nov; 34(33):8408-15. PubMed ID: 23932248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A non-covalent peptide-based strategy for siRNA delivery.
    Crombez L; Divita G
    Methods Mol Biol; 2011; 683():349-60. PubMed ID: 21053142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-penetrating peptides and peptide nucleic acid-coupled MRI contrast agents: evaluation of cellular delivery and target binding.
    Mishra R; Su W; Pohmann R; Pfeuffer J; Sauer MG; Ugurbil K; Engelmann J
    Bioconjug Chem; 2009 Oct; 20(10):1860-8. PubMed ID: 19788302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA.
    Ullah I; Chung K; Beloor J; Kim J; Cho M; Kim N; Lee KY; Kumar P; Lee SK
    J Drug Target; 2017 Apr; 25(4):320-329. PubMed ID: 27820977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides.
    Kang H; DeLong R; Fisher MH; Juliano RL
    Pharm Res; 2005 Dec; 22(12):2099-106. PubMed ID: 16184444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptides for nucleic acid delivery.
    Lehto T; Ezzat K; Wood MJA; El Andaloussi S
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt A):172-182. PubMed ID: 27349594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
    Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
    Zhang C; Newsome JT; Mewani R; Pei J; Gokhale PC; Kasid UN
    Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing endosomal escape for nanoparticle mediated siRNA delivery.
    Ma D
    Nanoscale; 2014 Jun; 6(12):6415-25. PubMed ID: 24837409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes.
    Juliano RL
    Ann N Y Acad Sci; 2006 Oct; 1082():18-26. PubMed ID: 17145920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.